Journal of Antivirals & Antiretrovirals
Open Access
ISSN: 1948-5964
ISSN: 1948-5964
Deryabin P.G., Mishin DV and Lvov D.K.
Scientific Tracks Abstracts: JAA
The development of an HCV vaccine is an obvious necessity as an overall 50% of treated patients do not experience signifi cant long-term benefi ts from the current regulated interferon and ribavirin-based combination therapy. Such a development, however, meets with many obstacles. No vaccine is yet available. Several vaccine approaches, essentially therapeutic, are currently in development. An in vitro model of an infection caused by diff erent HCV variants is developed. It has allowed isolating highly productive HCV variants from human blood serum samples. It was shown that isolated HCV variants propagate actively in cell cultures a various origin: PS, Vero, BHK-21, primary chick embryo fi broblasts. HCV strains induce cytopathogenic eff ect in the infected cell cultures, an infectious titers of HCV reaches 7,0-8,0 lg10TCD50/ml. Detailed identifi cation of isolated HCV variants ВГС is spent. It is shown that HCV strains have the ability to be neutralized by the antibodies containing in human blood serum using neutralization test, virus antigens can detect HCV antibodies by immune enzyme test, immune precipitation method, as well as by immune fl uorescence method. By RT PCR method it was possible to detect HCV RNA in cultural medium samples collected from HCV infected cell cultures. It was shown that HCV strains isolated don?t lose cytopathogenic properties and ability to propagate in cell cultures throughout many subcultures (15-20). HCV strains have an ability to induce HCV specifi c neutralizing antibodies in mice and rabbits. Data obtained testify to prospect of cultural inactivated vaccine against hepatitis C developing.